Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy

Bcl-2 family members: Dual regulators of apoptosis and autophagy

(2014) Beth Levine et al.   Autophagy

Malignant Precursor Cells Pre-Exist in Human Breast DCIS and Require Autophagy for Survival

(2010) Virginia Espina et al.   PLoS One

Autophagy facilitates the progression of ERα-positive breast cancer cells to antiestrogen resistance

(2009) Patricia V. Schoenlein et al.   Autophagy

Histone deacetylase inhibitor induced modulation of anti-estrogen therapy

(2009) Scott Thomas et al.   CANCER LETTERS

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

(2009) Richard L. Piekarz et al.   JOURNAL OF CLINICAL ONCOLOGY

Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization

(2008) M. A. Qadir et al.   BREAST CANCER RESEARCH AND TREATMENT

Selective Inhibition of Histone Deacetylase 2 Silences Progesterone Receptor-Mediated Signaling

(2008) E. Bicaku et al.   CANCER RESEARCH

ERα negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor

(2008) Jiang Fan et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance

(2008) J. S. Samaddar et al.   MOLECULAR CANCER THERAPEUTICS